EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management

Marie-Helene Denault, Cheryl Ho

Translational Cancer Research · 2023-03 · 12 (3) · 680-683

DOI: 10.21037/tcr-22-2843 ↗

Kurz gefasst

Editorial in der Zeitschrift Translational Cancer Research, 2023-03. Verfasst von Marie-Helene Denault und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pneumologie, Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Programmed death ligand-1 (PD-L1) tumor proportion score (TPS), although imperfect, is the best biomarker identified so far to guide the treatment of metastatic non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICI).Landmark trials in the firstline metastatic setting support its predictive value for response to immunotherapy in this population (1,2).As such, international guidelines recommend single agent anti-PD-1/ PD-L1 treatment in the PD-L1 ≥50% population, while those agents should be combined with either chemotherapy, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or both in PD-L1 1-49% and

Schlagwörter

Stichwörter der Autor:innen

Non-small cell lung cancer (NSCLC)immunotherapyprogrammed death ligand-1 (PD-L1)unresectable stage III

Autor:innen und Institutionen

  • Department of Pneumologie, Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada.
  • Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.

Zitieren

APA

Denault, M. H., & Ho, C. (2023). The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management. Translational Cancer Research, 12(3), 680-683. https://doi.org/10.21037/tcr-22-2843

Vancouver

Denault MH, Ho C. The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management. Translational Cancer Research. 2023;12(3):680-683. doi:10.21037/tcr-22-2843

BibTeX
@article{Denault2023,
  author = {Denault, Marie-Helene and Ho, Cheryl},
  title = {The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management},
  journal = {Translational Cancer Research},
  year = {2023},
  volume = {12},
  number = {3},
  pages = {680--683},
  doi = {10.21037/tcr-22-2843}
}
Kostenlos starten →